Kristen is a graduate of UCSD studying microbiology. As research assistant at Xycrobe Therapeutics, she is assisting the scientific team while learning what a microbiologists does in the lab in terms of new techniques, troubleshooting problems and planning strategies to design bacteria for therapeutic use. Kristen aims to use what she learns from her time at Xycrobe to do similar research in the medical field.
Thomas Hitchcock, Ph.D.
Founder and CEO
Jeong-Ho Kim is accomplished molecular and cell biologist with over 15 years of experience in the field of cellular signal transduction and gene expression. He earned his doctorate in Cell and Developmental Biology from the University of Illinois at Urbana-Champaign. At UIUC, he worked with Dr. Jie Chen whose major interest was the mTOR signaling network. He studied the shuttling mechanism of mTOR and function of mTOR in insulin resistance. He discovered mTOR plays a key role in IL-6-induced hepatic insulin resistance by regulating STAT3 activation and subsequent SOCS3 expression. His interest in insulin resistance and diabetes brought him to the Montminy lab at Salk Institute for Biological Studies as a postdoctoral fellow. He discovered hematopoiesis related phenotypes of CRTCs combination KO mice which made his interest switch to immune cells development. In addition, he uncovered novel function of CRTCs in bone marrow to regulate hematopoietic stem cell differentiation by modulating cytokine expression in stromal cells.
Michael is a hospitalist physician at New York University Langone Medical Center in New York. He holds a BA in Chemistry from Harvard University, and received his medical degree from New York University School of Medicne. He completed residency training in Pediatrics at New York University and Bellevue Hospital Center in New York, where he also served a year as Chief Resident. He is currently board certified in general pediatrics by the American Board of Pediatrics. Michael’s research has focused on functional genomics, using microarray technology to assess variable RNA expression in various human disease states. In addition to his scientific and medical endeavors, Michael also worked for several years for the Financial Services division of Oliver Wyman, a management consulting firm, where he worked on risk management and strategy for major financial institutions.
Kate has over 25 years sales and marketing experience in the life science research, medical device and pharmaceutical industries. Working on both the client and agency side, Kate has worked with some of the leading brands in the consumer medicine space. Prior to Xycrobe, she was a partner at Carling Communications and has worked with many brands in the aesthetic and medical dermatology space. Prior to moving into an agency setting she was Vice President of Marketing at Suneva Medical, Senior Director, Product Management and Marketing Communications at Solta Medical, Director of Marketing for Ciphergen BioSystems, and held a variety of sales, marketing and technical positions at life science companies in both Europe and the USA including Boehringer Mannheim, Genzyme, and Millipore, Inc. Kate holds a B.Sc (Hons) in Biological Sciences from University of Warwick, United Kingdom, and a Postgraduate Diploma in Strategic Marketing from Oxford College, United Kingdom.
Suzon Lommel Regulatory
Mun Su Rhee, Ph.D.
Associate Director, Research and Developent
Jeong Ho Kim, Ph.D
Blake is a recent graduate from LSU where he obtained a B.S. in Biological Engineering. He moved to San Diego shortly after to gain valuable experience in the biomedical industry, and found a great opportunity as an intern with Xycrobe Therapeutics. Here Blake assists the other scientists with their projects while practicing fundamental biochemical and microbiological lab techniques. Eventually he plans to attend graduate school in a biochemistry or biomedical engineering program.
Robert Miller, Esq.
Director of Business Development / Investor Relations
Mike Goonan, M.D.
Interim Medical Director
Mun is a Microbiologist at Xycrobe Therapeutics. He received his Ph.D of microbiology from Sung Kyun Kwan University, South Korea. He went to work as a researcher for two years at the bioscience R&D center of CJ Corp., the second largest amino acid producing company in the world to set up strain development tools for E. coli and Corynebacterium sp. using primarily transcriptomic analyses. He began work as a post-doctoral researcher and an assistant researcher in the Department of Microbiology and Cell Science, University of Florida working on strain development for biofuel and biochemicals. His research career can be described in three words: Bacterial Strain Development. He worked with E. coli, K. oxytoca, and B. subtilis strains for improvements of product yield, and optimized genetic manipulation techniques and fermentation conditions of novel strains, Bacillus coagulans, Paenibacillus sp, and Klebsiella variicola for strain developments. His research work was three-pronged: 1. Optimization of genetic tools for the engineering of a thermophilic lactic acid producing strain. 2. Identification of a novel bacterial strain and construction of high yield of D-lactic acid fermentation strain for the production of biodegradable plastics. 3. Engineering bacterial biocatalysts for production of biofuels and chemical feedstocks and biochemicals for pharmaceutical and nutraceutical applications. He also involved in another project about Xanthomonas sp. a bacterial pathogen and characterized important enzymes for prevention of citrus canker in many citrus species.
Thomas Hitchcock is the founder and CEO of Xycrobe Therapeutics. An entrepreneur in the biotech space, Thomas has been instrumental in bringing several medical technologies successfully to the dermatological and aesthetics markets. Thomas holds a doctorate in molecular genetics from Clemson University where he did his research on DNA damage and repair. He has completed postdoctoral training at both Duke University in the Biomedical Engineering Department and Yale University in the Program in Vascular Biology and Therapeutics where he was involved in ground-breaking research and development of in vitro engineered human cardiovascular and pulmonary tissues. He has also performed research at Weill Cornell Medical College in the Department of Oncology and Hematology where he studied multiple myeloma genetics. Prior to Xycrobe, he was the Director of Medical Affairs for Ulthera, Inc., and part of the team that brought their platform technology to acquisition in July 2014 by Merz pharmaceuticals. Thomas also currently travels the country lecturing to medical professionals about skincare and aesthetics in dermatology.
Robert oversees business development and investor relations for Xycrobe. Robert earned his B.A. in Psychology and Communication from The George Washington University, an M.T.A. degree in Event Management from GW (graduating first in his class), and a J.D. degree cum laude from Seton Hall Law School. While retired from practicing law, Robert holds the Series 56 designation and is a proprietary trader with T3 Trading Group on Wall Street. A savvy businessman, Robert is also President and Founder of Travel Advocates International, a B2B global hotel site selection company based in the New York City area. From its inception, Robert has led his company to double digit revenue growth each year. Robert also owns HBK Travel and GroupHotels.com.
Ms. Suzon D. Lommel serves as the regulatory expert on the Xycrobe team. Prior to joining Xycrobe, she was Global Vice President of Regulatory and Quality Affairs at Ulthera Inc. in Mesa Arizona which was acquired by Merz Inc in July 2014. Additional prior experience includes executive and senior roles at Breathe Technologies, Inc., FoxHollow Technologies, Inc., Advanced Stent Technology, and Boston Scientific. She has over 25 years of experience in developing quality systems in companies of all sizes and has extensive experience with the Food and Drug Administration as Author many 510k’s, IDE’s, PMA and International submissions. Ms. Lommel holds a degree in Physics from Moorpark College.
Copyright © 2017 Xycrobe Therapeutics, Inc. All rights reserved.